Economic analysis of ceftaroline fosamil for treating community-acquired pneumonia in Spain

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Torres, Antoni
• dc.contributor.author Bassetti, Matteo
• dc.contributor.author Welte, Tobias
• dc.contributor.author Rivolo, Simone
• dc.contributor.author Remak, Edit
• dc.contributor.author Peral, Carmen
• dc.contributor.author Charbonneau, Claudie
• dc.contributor.author Hammond, Jennifer
• dc.contributor.author Ansari, Wajeeha
• dc.contributor.author Grau Cerrato, Santiago
• dc.date.accessioned 2021-03-03T07:39:24Z
• dc.date.available 2021-03-03T07:39:24Z
• dc.date.issued 2020
• dc.description.abstract Background: Adults admitted to hospital with community-acquired pneumonia (CAP) impose significant burden upon limited hospital resources. To achieve early response and possibly early discharge, thus reducing hospital expenditure, the choice of initial antibiotic therapy is pivotal.Methods: A cost-consequences model was developed to evaluate ceftaroline fosamil (CFT) as an alternative to other antibiotic therapies (ceftriaxone, co-amoxiclav, moxifloxacin, levofloxacin) for the empiric treatment of hospitalized adults with moderate/severe CAP (PORT score III-IV) from the perspective of the Spanish National Health System (NHS).Findings: Compared with ceftriaxone, the model predicted an increase in the number of CFT-treated patients discharged early (PDE) (30.6% vs. 26.1%) while decreasing initial antibiotic failures (3.8% vs. 7.6%). For patients with pneumococcal pneumonia, CFT was cost-saving vs. ceftriaxone (by 1.2%) and significantly increased PDE (32.1% vs. 24.6%). CFT resulted in cost-saving vs. levofloxacin, due lower initial antibiotic therapy costs and increased PDE (30.6% vs. 14.9%). Moxifloxacin and co-amoxiclav early response rate of 53.63% and 54.24% resulted in cost neutrality vs. CFT, with direct comparison hampered by the significantly different early response criteria utilized in the literature.Conclusions: Despite a higher unit cost, CFT is a reasonable alternative to other agents for adults hospitalized with moderate/severe CAP, given the projected higher PDE achieved with similar or lower total costs.
• dc.format.mimetype application/pdf
• dc.identifier.citation Torres A, Bassetti M, Welte T, Rivolo S, Remak E, Peral C, et al. Economic analysis of ceftaroline fosamil for treating community-acquired pneumonia in Spain. J Med Econ. 2020 Feb; 23(2): 148-55. DOI: 10.1080/13696998.2019.1688819
• dc.identifier.doi http://dx.doi.org/10.1080/13696998.2019.1688819
• dc.identifier.issn 1369-6998
• dc.identifier.uri http://hdl.handle.net/10230/46650
• dc.language.iso eng
• dc.publisher Taylor & Francis
• dc.rights 2019 Pfizer Inc. Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. www.tandfonline.com/ijme
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
• dc.subject.keyword Ceftaroline fosamil
• dc.subject.keyword I10
• dc.subject.keyword I19
• dc.subject.keyword Spanish National Health System
• dc.subject.keyword Community-acquired pneumonia
• dc.subject.keyword Cost-consequences economic analysis
• dc.subject.keyword Early discharge
• dc.title Economic analysis of ceftaroline fosamil for treating community-acquired pneumonia in Spain
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion